Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  Clinuvel, de droom van elke belegger......

BioPharma« Terug naar discussie overzicht

Clinuvel, de droom van elke belegger......

Volgen
2.596 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 130 »» | Laatste | Omlaag ↓
  1. [verwijderd] 2 juli 2007 06:35
    quote:

    frank2you schreef:

    Hopelijk hervind CUV nu de stijgende lijn die men al sinds vorig jaar had ingezet en gaan we linea recta door naar de euro....

    Even 'n stapje terug. Bijtanken
    €0,55
    Code Last % Chg Bid Offer Open High Low Vol
    CUV 0.875 -4.89% 0.875 0.885 0.890 0.895 0.875 189,510
  2. [verwijderd] 2 juli 2007 08:49
    quote:

    controverse schreef:

    [quote=frank2you]
    Hopelijk hervind CUV nu de stijgende lijn die men al sinds vorig jaar had ingezet en gaan we linea recta door naar de euro....

    [/quote]

    Even 'n stapje terug. Bijtanken
    €0,55
    Code Last % Chg Bid Offer Open High Low Vol
    CUV 0.875 -4.89% 0.875 0.885 0.890 0.895 0.875 189,510

    Nog een stapje terug. Banden oppompen.

    Last $ +/- Bid Offer Open High Low Vol
    0.850 -0.070 0.850 0.885 0.890 0.895 0.850 235058

    Groet,
    Tom
  4. [verwijderd] 3 juli 2007 05:46
    Goede morgen.

    Welke updates kunnen we in de tweede helft van dit jaar nog verwachten.
    Start fase III in het homeland Australië en enkele startfases II.

    Momenteel koers onveranderd.

    Code Last % Chg Bid Offer Open High Low Vol
    CUV 0.850 0% 0.845 0.850 0.850 0.850 0.840 238,830

    Controvers
  8. [verwijderd] 4 juli 2007 09:02
    Financiele jaarrapportage.

    Positief.

    ABN 88 089 644 119 Level 11, 330 Collins Street T +61 3 9660 4900 clinuvel.com
    Melbourne Victoria 3000 F +61 3 9660 4999
    Australia
    Melbourne, Wednesday 4th July 2007

    End of Financial Year Report to Shareholders

    Dear Shareholder,

    Clinuvel has completed a company transforming year in FY07 and we are well placed to fulfil our strategic objective of bringing CUV1647 to market. The company is in excellent financial shape and we have recently commenced two Phase III clinical trials in Europe.
    Our progress in FY07 has substantially increased our potential whilst the scientific risk has materially decreased. A number of accomplished professionals have joined the Board of Directors and senior management is being added to the company. Institutional investors have recently injected capital at A$1.07 per share and the shares are currently undervalued based on analyst estimates.

    Finance, Cash Resources

    Clinuvel has a strong balance sheet with more than A$61 million in cash which we anticipate is sufficient to sustain research and development activities for approximately three years. We are aware that few if any developing pharmaceutical or biotech companies are in such an enviable financial position. Our strong cash position compares to our current market capitalisation of approximately A$270 million based on the June 29 closing price of A$0.92. Cash expenses in the latest quarter ending June 2007 totalled approximately A$1.65 million.

    The recent funding of A$26.4 million at A$1.07 was subscribed to by professional investors. In addition, our principal investor, Absolute Capital Management Holdings PLC has recently increased its stake by 2% to just under 20% (the maximum permissible without mounting a takeover bid). The support of the major shareholders is strong and they remain focused on helping to build Clinuvel into a global name in life-sciences.

    Clinical Appraisals

    Clinuvel has now successfully entered two Phase III clinical trials, one for PLE (sun allergy), the other for EPP (absolute sun intolerance). The latter is especially relevant because as a possible Orphan Drug (status granted for drugs treating rare diseases), we believe this trial may be completed in an accelerated manner, pending regulatory scrutiny. Orphan Drug status offers the company an accelerated path to registration in global markets.

    According to a study conducted by IMS Healthcare Inc. in the US, there are over 30 million people in the western world suffering from sun allergy, of which approximately 10% suffer from severe sun allergy. We have every reason to believe that CUV1647 can successfully address these symptoms.

    Cosmetic Applications

    We are frequently asked if CUV1647 could have use in cosmetic applications. While the company is not presently focusing on the cosmetic application, we cannot discount its long term potential.

    Communication

    An important objective of Clinuvel is to communicate effectively with its shareholders to build a substantial and confident investor base. Moreover, we are aiming to attract new investors via bimonthly investor conference calls and investor/analyst presentations worldwide.

    Share Price

    In the last 18 months, since new management was installed, the share price has risen substantially from a low of A$0.24 to a high of A$1.20. In recent weeks, our share price has been subjected to profit-taking. Although this may be expected after such a strong performance, the decline in share price now underrates both the present fundamentals as well as the potential of the company. The Australian broker Tolhurst Limited recently published research valuing Clinuvel shares at A$1.48.

    Conclusion

    With CUV1647, Clinuvel has a drug with the potential to change the lives and the quality of existence of those affected by light-sensitivity disorders.
    Helping improve lives and being financially successful are the twin aims of Clinuvel.
    We have completed a very successful FY07 and we look forward to the challenges in 2007/2008.

    Yours sincerely,
    Philippe Wolgen, MBA MD
    CEO Clinuvel Pharmaceuticals Ltd
    Clinuvel is listed in Australia (ASX: CUV) and Frankfurt (XETRA: UR9)
    ABN 88 089 644 119 Level 11, 330 Collins Street T +61 3 9660 4900 clinuvel.com
    Melbourne Victoria 3000 F +61 3 9660
  10. [verwijderd] 4 juli 2007 15:37
    Wat kunnen we nog in de 2e helft van 2007verwachten

    Value Drivers
    to look out for
    • Start Ph II AK in OTR
    • Start Ph II SU
    • Start Phase II PDT
    • Initiation of further
    Phase III trial sites in
    Europe and Australia

    Meetings
    & Events
    Clinuvel Investor
    Relations Road show
    25 -30 June, Europe
    Deze "Road show" stond niet op de site van Clinuvel. Kan iemand hierover iets meer vertellen of is het aangegeven tijdstip 25-30 juni misschien niet correct!

    Australian
    Biotechnology Summit
    1-2 August, Sydney
    CEO Presenting
    Ausbiotech

    Annual Conference
    21-24 October, Brisbane
    Clinuvel Attending

  16. [verwijderd] 6 juli 2007 18:37
    quote:

    cashmaster schreef:

    Ik moet toch vaker die glazen bol gaan oppoetsen :) Met een positief macrosentiment eindigen we toch maar weer netjes op 57 cent.
    Een fijn weekend gents
    Cashmaster bedankt voor je steun. Het lijkt er inderdaad op dat we niet onder de 50 duiken.
    Ook een fijn weekend gewenst.
2.596 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 130 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Pharming 0,779 +0,07 +9,56%
BAM 4,098 +0,33 +8,76%
AMG Critical Materials N.V. 17,260 +0,99 +6,08%
FASTNED 21,000 +1,20 +6,06%
Philips Koninklijke 29,460 +1,25 +4,43%
AZERION 1,420 +0,06 +4,41%
Akzo Nobel 64,400 +2,38 +3,84%
ALLFUNDS GROUP 5,550 +0,20 +3,74%
HEIJMANS KON 25,700 +0,90 +3,63%
RANDSTAD NV 44,900 +1,50 +3,46%
PostNL 1,275 +0,04 +3,41%
ASCX 1.245,45 +38,27 +3,17%
Sligro 12,560 +0,36 +2,95%
Flow Traders 18,650 +0,53 +2,92%
Alfen N.V. 13,530 +0,37 +2,81%
Avantium 1,956 +0,05 +2,73%
Heineken 80,880 +1,98 +2,51%
IMCD 158,000 +3,80 +2,46%
DSM FIRMENICH AG 121,850 +2,85 +2,39%
TomTom 5,285 +0,12 +2,32%
Sif Holding 14,820 +0,32 +2,21%
Brunel 8,880 +0,18 +2,07%
PROSUS 39,665 +0,77 +1,97%
SIGNIFY NV 21,560 +0,40 +1,89%
EXOR NV 100,000 +1,70 +1,73%
JUST EAT TAKEAWAY 13,900 +0,23 +1,68%
Air France-KLM 9,320 +0,15 +1,61%
AALBERTS NV 36,840 +0,56 +1,54%
UMG 23,860 +0,36 +1,53%
NX FILTRATION 4,600 +0,06 +1,32%
ADYEN NV 1.408,600 +17,60 +1,27%
JDE PEET'S 19,000 +0,22 +1,17%
BESI 113,950 +1,30 +1,15%
ACOMO 17,960 +0,20 +1,13%
Galapagos 26,400 +0,28 +1,07%
Ahold Delhaize 31,130 +0,28 +0,91%
Corbion 25,880 +0,22 +0,86%
ASMI 585,400 +4,80 +0,83%
TKH 38,180 +0,30 +0,79%
ForFarmers 3,250 +0,02 +0,78%
NN Group 44,940 +0,33 +0,74%
ArcelorMittal 23,430 +0,17 +0,73%
Nedap N.V. 57,400 +0,40 +0,70%
Fagron 18,540 +0,12 +0,65%
AEX 917,43 +5,77 +0,63%
Aperam 27,140 +0,16 +0,59%
Wereldhave 15,080 +0,08 +0,53%
Basic-Fit 22,960 +0,12 +0,53%
Kendrion 11,720 +0,06 +0,51%
UNILEVER PLC 58,700 +0,30 +0,51%
SHELL PLC 29,465 +0,15 +0,51%
NSI 20,900 +0,10 +0,48%
ASR Nederland 44,310 +0,21 +0,48%
AMX 898,81 +3,77 +0,42%
Eurocommercial Properties 25,300 +0,10 +0,40%
SBM Offshore 16,430 +0,06 +0,37%
B&S Group SA 4,700 +0,02 +0,32%
RENEWI 7,650 +0,02 +0,26%
WDP 24,360 +0,06 +0,25%
Aegon 5,788 +0,01 +0,14%

Dalers

instrument koers absoluut verschil relatief verschil
Vopak 41,480 -1,28 -2,99%
CM.COM 6,440 -0,16 -2,42%
INPOST 16,700 -0,30 -1,76%
Vastned 24,000 -0,35 -1,44%
Fugro 20,280 -0,20 -0,98%
THEON INTERNAT 10,600 -0,10 -0,93%
RELX 42,800 -0,30 -0,70%
KPN 3,670 -0,02 -0,60%
ABN AMRO BANK N.V. 16,370 -0,09 -0,55%
EBUSCO HOLDING 0,766 0,00 -0,52%
CTP 16,400 -0,08 -0,49%
ING 16,530 -0,08 -0,46%
Van Lanschot Kempen NV 42,000 -0,15 -0,36%
Wolters Kluwer 154,800 -0,55 -0,35%
ASML 757,300 -2,50 -0,33%
Arcadis 61,800 -0,20 -0,32%
Accsys 0,614 0,00 -0,16%
OCI 25,660 -0,04 -0,16%
vlag naam koers verschil relatief verschil
AEX 917,43 +5,77 +0,63%
AEX GR 3.585,07 +22,56 +0,63%
Germany40^ 19.401,70 -71,93 -0,37%
FTSE 100 8.320,76 +35,85 +0,43%
EURO50 5.049,08 0,00 0,00%
US30^ 42.305,80 0,00 0,00%
Nasd100^ 20.006,80 0,00 0,00%
US500^ 5.734,53 0,00 0,00%
Japan225^ 37.417,90 0,00 0,00%
VD-NEW 14,95 -0,23 -1,49%
#/^ Index indications calculated real time, zie disclaimer